Details for Patent: 9,173,858

Title:	Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract:	The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s):	Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Benoit (Bordeaux, FR)
Assignee:	Universite de Bordeaux (Bordeaux, FR) Centre Hospitalier Universitaire de Bordeaux (Talence, FR)
Filing Date:	Nov 16, 2012
Application Number:	13/678,902
Claims:	1. A method for treating an infant or small child for an infantile hemangioma, the method comprising administering to the infant or small child a medicament comprising a pharmaceutically acceptable and efficient dose of timolol. 2. The method of claim 1, wherein the medicament is for oral or topical administration. 3. A method for treating a hemangioma comprising administering to a patient in need thereof a pharmaceutically acceptable and efficient dose of timolol, wherein the hemangioma is a capillary hemangioma or capillary infantile hemangioma, and the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient. 4. The method of claim 1, wherein the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient. 5. The method of claim 4, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient. 6. The method of claim 3, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and an orodispersible dosage forms. 7. The method of claim 3, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 8. The method of claim 3, wherein the timolol is administered in a medicament for nasal, buccal, sublingual, or rectal administration. 9. The method of claim 4, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient. 10. The method of claim 1, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms. 11. The method of claim 1, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 12. The method of claim 1, wherein the timolol is administered in a medicament for nasal, buccal, sublingual, or rectal administration. 13. The method of claim 2, wherein the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient. 14. The method of claim 13, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient. 15. The method of claim 2, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms. 16. The method of claim 2, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams.